Press release
August 10, 2026
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (AXSM)
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI ® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO ® 2Q 2026